S 822 · in committee · niche
Scientific EXPERT Act of 2025
- healthcare
What this bill does
- The FDA must hold at least four science-focused meetings per year to discuss drug development for rare diseases.
- Drug makers, patient groups, and medical experts participate in meetings convened by the Reagan-Udall Foundation.
- The FDA reports whether it used meeting input when approving new drugs, with no new funding mechanism specified.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might requiring four annual FDA meetings on rare disease drugs change the timeline and cost of bringing new treatments to market?
- 02
What accountability mechanisms should exist if the FDA receives input at these meetings but doesn't incorporate it into approval decisions?
- 03
Should Congress specify funding for these meetings, or should the FDA absorb the costs within its existing budget?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-MN
Amy Klobuchar
Citizen cosponsors
0
In Congress
1/ 100
Senators cosponsoring
Introduced 2025-03-03
Joining the bill
Legislative timeline
2025-03-03 · senate · IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
2025-03-03 · IntroReferral
Introduced in Senate
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.